Impact of para aortic lymph node removal on survival following resection for pancreatic adenocarcinoma

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 888 KB, PDF document

Introduction: For PDAC patients undergoing resection, it remains unclear whether metastases to the paraaortic lymph nodes (PALN+) have any prognostic significance and whether metastases should lead to the operation not being carried out. Our hypothesis is that PALN + status would be associated with short overall survival (OS) compared with PALN-, but longer OS compared with patients undergoing surgical exploration only (EXP). Methods: Patients with registered PALN removal from the nationwide Danish Pancreatic Cancer Database (DPCD) from May 1st 2011 to December 31st 2020 were assessed. A cohort of PDAC patients who only had explorative laparotomy due to non-resectable tumors were also included (EXP group). Survival analysis between groups were performed with cox-regression in a multivariate approach including relevant confounders. Results: A total of 1758 patients were assessed, including 424 (24.1%) patients who only underwent explorative surgery leaving 1334 (75.8%) patients for further assessment. Of these 158 patients (11.8%) had selective PALN removal, of whom 19 patients (12.0%) had PALN+. Survival analyses indicated that explorative surgery was associated with significantly shorter OS compared with resection and PALN + status (Hazard Ratio 2.36, p < 0.001). No difference between PALN + and PALN- status could be demonstrated in resected patients after controlling for confounders. Conclusion: PALN + status in patients undergoing resection offer improved survival compared with EXP. PALN + should not be seen as a contraindication for curative intended resection.

Original languageEnglish
Article number214
JournalBMC Surgery
Volume23
Issue number1
ISSN1471-2482
DOIs
Publication statusPublished - 2023

Bibliographical note

Funding Information:
Open access funding provided by Royal Library, Copenhagen University Library. The study was funded by a grant from the Novo Nordisk Foundation (#NNF19OC0055183) to MS.

Publisher Copyright:
© 2023, The Author(s).

    Research areas

  • Long term survival, Lymph station 16, Pancreatic cancer

ID: 372809339